Department of Cardiology, Boston Children's Hospital, Boston, MA.
Department of Pediatrics, Harvard Medical School, Boston, MA.
Crit Care Med. 2021 Mar 1;49(3):e291-e303. doi: 10.1097/CCM.0000000000004822.
Hemoptysis is uncommon in children, even among the critically ill, with a paucity of epidemiological data to inform clinical decision-making. We describe hemoptysis-associated ICU admissions, including those who were critically ill at hemoptysis onset or who became critically ill as a result of hemoptysis, and identify predictors of mortality.
Retrospective cohort study. Demographics, hemoptysis location, and management were collected. Pediatric Logistic Organ Dysfunction-2 score within 24 hours of hemoptysis described illness severity. Primary outcome was inhospital mortality.
Quaternary pediatric referral center between July 1, 2010, and June 30, 2017.
Medical/surgical (PICU), cardiac ICU, and term neonatal ICU admissions with hemoptysis during or within 24 hours of ICU admission.
No intervention.
There were 326 hemoptysis-associated ICU admissions in 300 patients. Most common diagnoses were cardiac (46%), infection (15%), bronchiectasis (10%), and neoplasm (7%). Demographics, interventions, and outcomes differed by diagnostic category. Overall, 79 patients (26%) died inhospital and 109 (36%) had died during follow-up (survivor mean 2.8 ± 1.9 yr). Neoplasm, bronchiectasis, renal dysfunction, inhospital hemoptysis onset, and higher Pediatric Logistic Organ Dysfunction-2 score were independent risk factors for inhospital mortality (p < 0.02). Pharmacotherapy (32%), blood products (29%), computerized tomography angiography (26%), bronchoscopy (44%), and cardiac catheterization (36%) were common. Targeted surgical interventions were rare. Of survivors, 15% were discharged with new respiratory support. Of the deaths, 93 (85%) occurred within 12 months of admission. For patients surviving 12 months, 5-year survival was 87% (95% CI, 78-92) and mortality risk remained only for those with neoplasm (log-rank p = 0.001).
We observed high inhospital mortality from hemoptysis-associated ICU admissions. Mortality was independently associated with hemoptysis onset location, underlying diagnosis, and severity of critical illness at event. Additional mortality was observed in the 12-month posthospital discharge. Future directions include further characterization of this vulnerable population and management recommendations for life-threatening pediatric hemoptysis incorporating underlying disease pathophysiology.
咯血在儿童中并不常见,即使在危重病患儿中也是如此,因此缺乏可用于临床决策的流行病学数据。我们描述了与咯血相关的 ICU 入院情况,包括在咯血发作时即处于危重病状态的患者,以及因咯血而成为危重病患者的患者,并确定了死亡率的预测因素。
回顾性队列研究。收集了人口统计学资料、咯血部位和处理方法。在咯血后 24 小时内,使用儿科逻辑器官功能障碍-2 评分描述疾病严重程度。主要结局是院内死亡率。
2010 年 7 月 1 日至 2017 年 6 月 30 日,一家四级儿科转诊中心。
有咯血的内科/外科(PICU)、心脏 ICU 和足月新生儿 ICU 入院患者,这些患者在 ICU 入院期间或入院后 24 小时内出现咯血。
无干预措施。
在 300 名患者中,有 326 例与咯血相关的 ICU 入院患者。最常见的诊断为心脏病(46%)、感染(15%)、支气管扩张(10%)和肿瘤(7%)。不同的诊断类别患者的人口统计学、干预措施和结局存在差异。总体而言,79 名患者(26%)院内死亡,109 名患者(36%)在随访期间死亡(幸存者平均随访 2.8±1.9 年)。肿瘤、支气管扩张、肾功能不全、院内咯血发作和较高的儿科逻辑器官功能障碍-2 评分是院内死亡率的独立危险因素(p<0.02)。药物治疗(32%)、血液制品(29%)、计算机断层扫描血管造影(26%)、支气管镜检查(44%)和心导管检查(36%)是常见的治疗方法。针对性的外科手术干预很少见。在幸存者中,15%的患者出院时需要新的呼吸支持。在死亡患者中,93 例(85%)在入院后 12 个月内死亡。对于存活 12 个月的患者,5 年生存率为 87%(95%CI,78-92),且只有肿瘤患者的死亡风险仍然存在(对数秩检验 p=0.001)。
我们观察到与咯血相关的 ICU 入院患者的院内死亡率较高。死亡率与咯血发作部位、潜在诊断以及事件发生时的严重程度独立相关。在出院后 12 个月内还观察到额外的死亡。未来的研究方向包括进一步描述这一脆弱人群,并根据潜在疾病的病理生理学制定危及生命的儿科咯血的治疗建议。